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 Abstract 25 
Complement is a major defense system of innate immunity and aimed to destroy microbes. 26 
One of the central complement regulators is factor H, which belongs to a protein family that 27 
includes CFHL1 and five factor H-related (CFHR) proteins. Recent evidence shows that 28 
factor H family proteins (factor H and CFHRs) are associated with diverse and severe human 29 
diseases, and are also utilized by human-pathogenic microbes for complement evasion. 30 
Therefore, dissecting the exact functions of the individual CFHR proteins will provide 31 
insights into the pathophysiology of such inflammatory and infectious diseases, and will 32 
define the therapeutic potential of these proteins. 33 
34 
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Complement, an innate defense system 35 
 36 
Complement is an essential part of innate immunity, and plays a central role in the elimination 37 
of microbes, clearing of immune complexes and damaged self cells, and also in modulating 38 
the adaptive immune response [1]. Inappropriate complement function, however, leads to 39 
various human diseases [2]. Due to its vital role in homeostasis, this network of proteins 40 
receives increasing attention from immunologists and clinical oriented researchers. It is 41 
therefore of general interest to understand the physiologic function of this defense system at 42 
the molecular level. 43 
 44 
The complement system consists of ~35 proteins that are present in body fluids or on 45 
cell and tissue surfaces, and is activated in a cascade-like manner by three major pathways 46 
[1]. The alternative pathway is activated continuously at a low rate by the spontaneous 47 
hydrolysis of the central component C3, the lectin pathway is initiated by mannose binding 48 
lectin or ficolins that recognize microbial carbohydrates, and the classical pathway is 49 
activated by binding of C1q to antigen bound immunoglobulins. Enzymatic steps generate 50 
active fragments of complement components, and trigger further amplification. The three 51 
pathways merge at the level of C3, which upon activation is cleaved into C3a and C3b. C3a 52 
acts as an anaphylatoxin and antimicrobial substance. C3b binds covalently to surfaces, and as 53 
opsonin aids phagocytosis of target cells. C3b is also part of the C3 and C5 convertase 54 
enzymes, which by cleaving C3 and C5 further amplify complement activation. This step may 55 
initiate the terminal pathway, which leads to the assembly of membrane attack complexes that 56 
form pores on target cells and cause lysis.  57 
 58 
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Complement activation, which by the elimination of invading microbes is important 59 
for host defense, may also damage host tissues. To prevent this, the human body utilizes fluid-60 
phase and membrane anchored complement regulators. Several regulators act at the level of 61 
C3, and either facilitate the disassembly of the C3 convertases (decay accelerating activity) or 62 
act as cofactors for the serine protease factor I, which in the presence of a cofactor cleaves 63 
and inactivates C3b and C4b. Thus further activation is inhibited. With a concentration of 64 
300-800 mg/L, factor H (CFH) is one of the most abundant human plasma proteins and is an 65 
important complement regulator that acts both in fluid phase and on tissue surfaces [3]. 66 
 67 
The human factor H protein family 68 
 69 
CFH is the best characterized member of the CFH protein family. This family of closely 70 
related proteins includes the complement regulators CFH and CFH-like protein 1 (CFHL1), as 71 
well as five CFH-related proteins CFHR1, CFHR2, CFHR3, CFHR4 and CFHR5 [4]. The 72 
individual CFH family proteins share common features, as these plasma glycoproteins are 73 
produced primarily in the liver, they are exclusively composed of individually folding 74 
domains termed short consensus repeats (SCRs; also known as complement control protein 75 
modules), and they show immunological cross-reactivity. The relatedness of the individual 76 
proteins is further reflected on the genomic level, by the tandem arrangement of the CFH 77 
gene and the five CFHR genes in the CFH gene cluster on human chromosome 1q32 (Figure 78 
1A). 79 
 80 
CFH is composed of 20 SCR domains. Two major functional regions are located at the 81 
opposite ends of the protein. The N-terminal four SCR domains (SCRs 1-4) display 82 
complement regulatory activity by facilitating the decay of the C3 convertase and acting as a 83 
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cofactor for factor I [3]. The C-terminus of the protein (SCRs 19-20) mediates surface binding 84 
and target recognition [5]. This C-terminal region includes binding sites for several ligands, 85 
such as C3b, C3d, heparin, cell surface glycosaminoglycans and microbial virulence factors 86 
[6]. Attached to the surface of host cells and membranes, such as the glomerular basement 87 
membrane, CFH inhibits complement activation [7,8]. Although CFH possesses multiple 88 
binding sites for C3b and heparin (Figure 1B), apparently the C-terminus represents the 89 
major ligand recognition site of the intact protein. This feature is explained by a folded-back 90 
conformation of the protein in solution [5]. 91 
 92 
The CFHL1 protein, which is derived from the CFH gene by means of alternative 93 
splicing, is composed of the seven N-terminal domains of CFH and has a unique C-terminal 94 
four amino acids extension. Consequently, CFHL1 shares ligand binding and complement 95 
regulatory activity with the N-terminus of CFH [9]. 96 
 97 
The individual CFHR proteins have 4 to 9 SCR domains. A homology alignment of 98 
SCRs among CFH family proteins reveals two major conserved regions (Figure 1B). The N-99 
terminal SCRs of all five CFHR proteins are related to each other, and show homology to 100 
SCRs 6-9 of CFH. In CFH these three domains include binding sites for heparin, C-reactive 101 
protein (CRP), and for several microbial surface proteins. The C-termini of CFHRs are also 102 
homologous to each other and to the C-terminal surface binding region of CFH. The extent of 103 
identity of the three or two most C-terminal SCRs of the CFHR proteins with the C-terminal 104 
domains of CFH ranges from 100%, i.e. SCRs with full sequence identity, to 37% at the 105 
amino acid level (Figure 1). Interestingly, the non-human CFHR proteins identified so far 106 
show very similar N- and C-termini as their human counterparts, thus indicating related 107 
functions [10,11]. The homology of CFHR domains with SCRs of CFH implies similar ligand 108 
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binding and functional relatedness. For CFHR3, CFHR4 and CFHR5 C3b binding, for 109 
CFHR3 and CFHR5 heparin binding, and for CFHR5 CRP binding was reported [12,13]. (See 110 
Table 1 for known CFHR ligands).  111 
 112 
Sequence alignments among CFHR proteins also identify subgroups of related 113 
domains, indicating functional redundancy, as well as differences. CFHR1 and CFHR2 show 114 
a very similar domain composition, and their two N-terminal domains have almost complete 115 
sequence identity. However, the three C-terminal domains of CFHR1, but not of CFHR2, are 116 
almost identical with SCRs 18-20 of CFH. CFHR3 and CFHR4 are also similar to each other, 117 
again indicating overlapping activities. However CFHR3, but not CFHR4 has a domain 118 
homologous to SCR7 of CFH, which in CFH mediates heparin and M protein binding. This 119 
might explain why CFHR3, but not CFHR4, binds heparin and M protein [12,14]. Several 120 
CFHR domains show rather low level of identity to SCRs of CFH, but are very similar to each 121 
other, e.g. SCRs 1-2 of CFHR1, CFHR2 and CFHR5. In addition, CFHR5 differs from the 122 
other CFHR proteins by its unique middle region. These structural features may translate into 123 
both functional redundancy and unique functions.  124 
 125 
Functions of the CFHR proteins 126 
 127 
The CFHR proteins lack the potent complement regulatory activity of CFH, i.e. cofactor and 128 
decay accelerating activities [12,15]. This difference is consistent with the lack of the N-129 
terminal complement regulatory region of CFH for each CFHR protein. However, a 130 
complement modulatory activity, in form of a CFH cofactor enhancing activity was reported 131 
for CFHR3 and CFHR4 [12]. The exact mechanism of this synergistic activity is unknown, 132 
but is probably related to the C3b binding capacity of the proteins. Similarly, for CFHR5 133 
relatively weak cofactor and decay accelerating activities were described [13].  134 
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 135 
As all CFHR proteins share a common N-terminal region, a similar function is predicted 136 
for these proteins. In addition, the conservation of the C-terminal regions, which are related to 137 
the surface recognition region of CFH, suggests that CFH family proteins share surface 138 
binding activity, and that some CFHR proteins bind to the same or related ligands, as CFH. 139 
However, the sequence differences indicate differences in binding affinities or distinct ligand 140 
interactions. CFHR3, CFHR4, CFHR5 and CFH bind C3b, suggesting for each protein a role 141 
in C3b inactivation and thus a role in complement regulation. CFH has three C3b binding 142 
sites which bind different parts and fragments of C3b [16]. As CFHR3 and CFHR4 also bind 143 
the C3d fragments [17], the two proteins may compete with CFH for C3d binding. Based on 144 
the common and distinct features of CFH family proteins, three major scenarios are proposed 145 
for the role of CFHR proteins on biological surfaces (Figure 2): (i) complement regulatory 146 
activity or synergistic activity with CFH, such as described for CFHR3, CFHR4 and CFHR5; 147 
(ii) particularly for CFHR1 and CFH, which have almost identical C-terminal binding 148 
domains, competition for the same surfaces and ligands may result in less surface bound CFH 149 
and, consequently, in lower regulatory activity; and (iii) independent surface binding and 150 
independent function for CFHRs and CFH. It will be exciting to define the exact functions 151 
and to dissect differences of CFHR proteins in fine tuning of complement activation, and to 152 
identify so far unkown unique biological roles. 153 
 154 
The expression levels of CFHRs seem to vary in different tissues. Due to the high 155 
similarity of the proteins to each other and to CFH, at present only a few specific antibodies 156 
are available, making it difficult to determine the concentration of each CFHR protein in body 157 
fluids. Changes in concentrations, however, can be determined using a comparative approach. 158 
In the middle-ear effusion fluid of patients with otitis media with effusion, where 159 
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inflammation and complement activation is observed, the concentration of CFHR proteins is 160 
enhanced in comparison to plasma [18]. In autistic persons CFHR1 levels are increased in the 161 
brain [19]. 162 
 163 
The plasma concentrations of CFHR proteins are comparable to that of other complement 164 
components. CFHR1 has an apparent plasma concentration of about 50-100 µg/ml, which is 165 
comparable to that of terminal pathway components, like C6, C7 and C8. This concentration 166 
is about 10-20% of that of CFH and translates into an approximately threefold molar 167 
difference. Even though CFHR5 plasma levels are relatively low (ca. 5 µg/ml) [13], CFHR5 168 
is identified in complement containing deposits in the kidney, which suggests a local role in 169 
complement regulation [20]. Various expression levels of CFHR mRNA were detected also in 170 
different mouse organs [21]. Altogether these data suggest that CFHR proteins might be 171 
locally important. 172 
  173 
Factor H family proteins in human diseases 174 
 175 
Mutations, polymorphisms as well as large deletions within the CFH gene cluster are 176 
associated with several human diseases (summarized in Table 2), such as the kidney diseases 177 
atypical hemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis 178 
type II (MPGN II), and the retinal disease age-related macular degeneration (AMD). Based on 179 
the overlapping functions of the individual CFHR proteins, common pathophysiological 180 
principles are proposed for these human disorders in terms of defective local complement 181 
regulation. 182 
  183 
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Atypical hemolytic uremic syndrome (aHUS). aHUS is a severe kidney disease 184 
characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute renal 185 
failure. Mutations in complement genes account for approximately 50% of aHUS cases [22]. 186 
The known mutations affect the genes coding for CFH, membrane cofactor protein, factor I, 187 
factor B and C3 [23]. The mutations result in defective alternative pathway regulation, which 188 
leads to complement mediated tissue damage in the kidney. 189 
 190 
The majority of CFH mutations are heterozygous and affect the C-terminal surface 191 
binding region. Mutant CFH proteins show reduced binding to C3b, heparin and endothelial 192 
cells [6]. In addition, ~10% of aHUS patients have autoantibodies that bind to the most C-193 
terminal domain of CFH and, by blocking CFH binding, they inhibit complement regulation 194 
on the cell surface [24,25]. Recently, a mouse model for CFH-associated aHUS was reported. 195 
Mice that express a truncated CFH molecule, which lacks the surface recognition region (i.e. 196 
ΔSCRs 16-20) develop aHUS spontaneously. Thus demonstrating that defective surface 197 
recognition of CFH eventuates in aHUS [26].  198 
 199 
In some aHUS patients, large genomic deletions were found. The missing 200 
chromosomal fragments are flanked by duplicated regions with more than 98% sequence 201 
identity, suggesting that the deletion is caused by non-allelic homologous recombination 202 
(Figure 1A). Two chromosomal breakpoints have been defined so far. One breakpoint results 203 
in deletion of CFHR3 and CFHR1 [27]. Such a homozygous CFHR1 and CFHR3 deficiency 204 
occurs in 10-16% of aHUS patients as compared to 2-4% of control groups, and heterozygous 205 
deletions are also more frequent among aHUS patients (35% versus 9%) [27]. The absence of 206 
CFHR1 and CFHR3 proteins in plasma may affect fine tuning of the complement cascade. 207 
However, the deletion of the CFHR1 and CFHR3 genes in healthy individuals indicates that 208 
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the lack of these proteins can at least be partially compensated for. Interestingly, this deletion 209 
predisposes for the development of anti-CFH autoantibodies, which block CFH recognition 210 
function [28]. The second breakpoint within the same duplicated regions results in deletion of 211 
exons 22 and 23 of CFH, the complete CFHR3 gene and exons 1-4 of CFHR1. This leads to a 212 
hybrid CFH-CFHR1 gene, whose protein product has SCRs 1-18 derived from the CFH gene, 213 
and the two C-terminal domains from CFHR1 [29]. This hybrid CFH-CFHR1 protein has 214 
defective recognition functions. Given the presence of several duplicated sequences within 215 
this gene cluster (Figure 1A), further deletions and genomic rearrangements are predicted.  216 
 217 
Additional changes that affect this gene cluster have been reported. De novo gene 218 
conversion between CFHR1 and CFH results in the exchange of two residues within SCR20. 219 
Such a mutant CFH protein shows reduced binding to heparin and to cell surfaces [30]. Five 220 
heterozygous CFHR5 gene variants have also been identified in aHUS patients (9 out of 45) 221 
and/or in healthy controls (4 out of 80) [31]. 222 
 223 
Membranoproliferative glomerulonephritis type II (MPGN II). MPGN II is a severe 224 
kidney disease characterized with electron-dense deposits within the glomerular basement 225 
membrane, and mesangial cell proliferation. Apparently, MPGN II is associated with 226 
inappropriate complement regulation, and MPGN patients show low C3 plasma levels and 227 
enhanced amount of C3 activation products in plasma [32]. Several conditions have been 228 
described to cause MPGN II [32]: (i) the absence of CFH in plasma, due to mutations of 229 
essential cysteine residues that result in a block of protein secretion; (ii) secretion of a 230 
mutated CFH protein which shows reduced regulatory activity in plasma [33]; (iii) 231 
autoantibodies against CFH that block regulatory function in fluid phase; and (iv) 232 
autoantibodies against the C3 convertase (also termed C3 nephritic factor), which stabilizes 233 
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the C3 convertase and enhances complement activation [32]. The majority of CFH genetic 234 
mutations identified so far appear in homozygous or compound heterozygous form, resulting 235 
in lack of CFH function in plasma. CFH deficient pigs [34] and CFH knockout mice [35] 236 
develop glomerulonephritis due to uncontrolled complement activation in plasma. 237 
Interestingly, for some MPGN II patients ocular lesions have been reported, indicating 238 
formation of related deposits at the glomerular basement membrane and the Bruch’s 239 
membrane [32].  240 
 241 
For CFHR5 three allelic variants are reported which are more frequent in MPGN II 242 
patients, as compared to healthy controls [36]. The distribution of the CFHR5 protein 243 
correlates with that of other complement activation products in glomerular immune deposits, 244 
which indicates a local regulatory function of CFHR5 in the kidney [20]. In addition, the rat 245 
homolog of human CFHR5 is also expressed in the kidney and displays complement 246 
regulatory activity [36].  247 
 248 
Age-related macular degeneration (AMD). AMD is a leading cause for irreversible 249 
vision loss in developed countries and affects millions of elderly individuals worldwide. 250 
AMD is associated with immune deposits (drusen) formed between retinal pigment epithelial 251 
cells and Bruch’s membrane [37]. Proteomics and histological analyses demonstrate the 252 
presence of complement proteins and complement activation products in drusen, suggesting a 253 
local role for complement in the pathophysiology of this disease [38]. A recent study has 254 
demonstrated that during inflammation complement components accumulate in the eye [39]. 255 
 256 
In AMD patients both protective and disease-associated variants of CFH were reported. 257 
In particular a Tyr402His exchange within SCR7 of CFH and CFHL1 strongly increases the 258 
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risk for AMD [40]. Both the CFHH402 and CFHL1H402 variants show reduced binding to 259 
heparin and CRP [41,42]. The protective role of CFH in the eye is also shown by the analysis 260 
of aged CFH knockout mice, which develop ocular lesions similar to those seen in human 261 
patients [43]. 262 
 263 
Curiously, and in contrast to aHUS, the deletion of the CFHR1 and CFHR3 genes has a 264 
protective effect in AMD [44,45]. The frequency of homozygous CFHR1/CFHR3 deletion 265 
shows large variation between different ethnic groups, and occurs in 17.3% of African 266 
populations, 15.9% of African Americans, 6.8% of Hispanic, 4.7% of Caucasian, and 2.2% of 267 
Chinese ethnic group [45]. In line with this, AMD is more rare among African Americans, 268 
compared to Caucasian and Chinese populations [46]. Based on the high sequence similarity 269 
of the C-terminal surface binding regions of CFHR1 and CFH, CFHR1 may act as a 270 
competitor for CFH. By inhibiting CFH surface attachment, CFHR1 may reduce the local 271 
complement inhibitory and anti-inflammatory activity (Figure 2C). Thus, the lack of CFHR1 272 
in the eye may result in enhanced protection against complement activation. 273 
 274 
For AMD, mutations in the complement components C3, factor B and C2 have also been 275 
reported [47,48]. In addition, the complement activation products C3a and C5a were shown to 276 
contribute to neovascularization in the diseased eye [49]. These data altogether indicate that 277 
complement dysregulation contributes to the development of AMD.  278 
 279 
Infectious diseases. Numerous human-pathogenic microbes, including bacteria, fungi, 280 
viruses and parasites, recruit host complement regulators from plasma and utilize these 281 
regulators for complement and immune evasion [50]. This exploitation of host regulators by 282 
microbes is a rapidly developing research field, and because the number of known 283 
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CFH/CFHL1 binding microbes and proteins is rapidly expanding [50], here we focus on 284 
CFHR proteins.  285 
 286 
Several Borrelia species, the causative agents of Lyme borreliosis, bind CFH and for 287 
Borrelia burgdorferi CFH binding seems to correlate directly with serum resistance [51,52]. 288 
The five identified borrelial CFH binding proteins, which all can be expressed by one strain, 289 
show different binding affinities and bind also CFHL1 (CRASP1 and CRASP2) or CFHR1 290 
(CRASP3, CRASP4 and CRASP5) [53]. CRASPs 3-5 are members of the polymorphic Erp 291 
(OspE/F-related proteins) family, whereas CRASP1 and CRASP2 show no sequence 292 
similarity. The structure of CRASP1 of B. burgdorferi was determined and shown to form 293 
homodimers, with a cleft between the monomers, that possibly allows binding of the C-294 
termini of CFH and CFHL1 [54]. Similarly, CFHR1 binds to CRASPs also via its C-terminus, 295 
and for CRASP5 a competition between CFHR1 and CFH for binding was demonstrated, 296 
which was accompanied with reduced CFH mediated complement regulatory activity [53]. 297 
Thus, CFHR1 can be advantageous for the host as it prevents CFH binding to the pathogen 298 
(Figure 2B). As these microbial proteins bind the host ligands with different affinities, and as 299 
their expression is developmentally regulated and varies during the infection process, it is 300 
hypothesized that regulation of CRASP gene expression and protein translocation helps the 301 
pathogen to optimally adapt to its host. 302 
 303 
M proteins of streptococci have a protruded fibrillar structure with both conserved and 304 
variable regions that bind a number of host proteins, including complement regulators, 305 
plasminogen, IgG and albumin [55]. CFH, CFHL1 and CFHR3, but not CFHR4, are bound by 306 
the M5 protein [14]. There is a large number of serotypes with distinct M protein sequences, 307 
which differ in their ability to bind CFH. It has been proposed that M protein bound CFH 308 
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family proteins promote complement evasion of steptococci. However, phagocytosis 309 
resistance of M protein expressing streptococci is also mediated by other factors [55] and is 310 
not necessarily dependent on CFH [56]. In addition, Streptococcus pyogenes binds both 311 
CFHR1 and CFH with the Scl1 surface protein [57]. Multiplicity and coordinated 312 
simultaneous expression of such surface proteins that bind several host molecules are likely 313 
important for immune evasion of pathogens. The relevance of the individual CFH family 314 
proteins for complement evasion of streptococci needs to be evaluated in functional assays. 315 
 316 
Expression of the Por1A protein enables Neisseria gonorrhoeae to bind CFH and 317 
CFHR1, and weakly also CFHL1. Por1A binding is specific to human CFH and contributes to 318 
human-restricted pathogenicity [58]. The Tuf protein, a translation elongation factor of 319 
Pseudumonas aeruginosa, binds CFH, CFHL1 and CFHR1. It has been shown that CFH 320 
retains its complement regulatory activity when bound to Tuf [59]. Leptospira interrogans 321 
binds CFH and CFHR1, but not CFHL1, with the LenA (or LfhA) outer surface protein [60]. 322 
Although L. interrogans has five additional paralogs of LenA, only one of them binds CFH 323 
[61]. The mold Aspergillus fumigatus binds CFH, CFHL1 and CFHR1 but the microbial 324 
ligands have not yet been identified [62]. Furthermore, CFHR3 and CFHR4 were shown to 325 
bind to C3b-opsonized pneumococci [12], and may cooperate with CFH for complement 326 
inhibition (Figure 2A). 327 
 328 
Thus, a wide range of structurally and functionally different microbial surface 329 
molecules bind CFH family proteins. The binding sites generally show a preference, however, 330 
for SCR7 of CFH and CFHL1, and the C-termini of CFH and CFHR1. Because of the highly 331 
related structure of the CFHR proteins, it is expected that additional CFHRs, like CFHR2 and 332 
CFHR5, bind to human-pathogenic microbes. Such a surface decoration allows the pathogen 333 
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to utilize specific and distinct host proteins for immune- and, in particular, for complement 334 
evasion. CFHR proteins might be advantageous for the pathogen, in the case of cooperation 335 
with CFH, or advantageous for the host, when they interfere with CFH binding to pathogens. 336 
An additional, so far poorly explored aspect is the possible role of acquired CFH family 337 
proteins in cellular adhesion [63,64]. This could be advantageous for the pathogens to 338 
facilitate contact with host cells.  339 
 340 
Conclusion 341 
 342 
Although the exact functions of CFHR proteins are still not well defined, their involvement in 343 
various diseases clearly indicates a specific and important role for this group of proteins. The 344 
organs that are mainly affected in these diseases, the glomerular basement membrane in the 345 
kidney and the Bruch’s membrane in the eye, have in common that they lack endogenous 346 
complement regulators, and rely on bound CFH for complement inhibition. Based on their 347 
known synergistic (CFHR3, CFHR4 and CFHR5) and antagonistic (CFHR1) effects on CFH 348 
function, the CFHR proteins are probably involved in fine tuning of local complement 349 
activation. The lessons learned from human diseases, where deficiency of CFHR1 and 350 
CFHR3 is a risk factor in one disease (aHUS), and a protective factor in another disease 351 
(AMD), suggests that a similar dichotomy in CFHR function on pathogens might exist. The 352 
structural differences also imply distinct roles, possibly unrelated to complement, for the 353 
individual proteins. To decipher these unique functions is the major challenge for future work. 354 
Expanding our knowledge on the genetics, tissue expression and physiological functions of 355 
the CFHR proteins will certainly help to better understand the role of these proteins in the 356 
pathomechanisms of the discussed diseases and in the immune evasion of pathogenic 357 
microbes. 358 
359 
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Open questions box 364 
A general role for the CFHR proteins in the regulation of complement activation is emerging, 365 
but there are still many important questions regarding their direct functions. 366 
1. There are fragmental data on tissue expression, distribution and concentration in body 367 
fluids for the individual CFHR proteins. Due to the high sequence similarity on both 368 
the nucleotide and amino acid levels, currently CFHR specific DNA probes and 369 
antibodies are not available. Determining the amounts of CFHR proteins is hampered 370 
by the immunological cross-reactivity between the CFHR proteins and CFH/CFHL1.  371 
It will be a challenge to analyze both the relative CFHR mRNA levels and CFHR 372 
protein concentrations in various tissues and to correlate these parameters in order to 373 
evaluate the biological relevance of the individual CFHRs.  374 
2. An association with plasma lipoproteins has so far been demonstrated for CFH, 375 
CFHR1, CFHR2, CFHR4 and CFHR5. Thus, CFH family proteins may participate in 376 
lipid transport or may regulate lipid homeostasis. The relevance of lipoprotein 377 
association needs to be addressed further.  378 
3. It needs to be demonstrated in functional assays if CFHR proteins indeed modulate 379 
CFH activity to a biologically relevant extent. Analysis of the activity of these proteins 380 
on human tissues and in complement resistance of microbes will be helpful to 381 
understand the involvement of CFHR proteins in inflammatory processes and 382 
infectious diseases. 383 
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4. More data are needed on the functions of the CFHR proteins in order to understand 384 
their physiological roles. Especially CFHR1 and CFHR2 are poorly characterized to 385 
date, but also more detailed analysis of the other CFHR proteins in functional assays 386 
and the identification of new ligands will be informative. These studies are expected to 387 
define novel and unique functions for the members of this group of proteins. 388 
389 
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Figure legends 555 
 556 
Figure 1. The human complement Factor H gene cluster and structure of the various 557 
proteins. 558 
(A) The human Factor H (CFH) gene cluster includes six genes which show a consecutive 559 
arrangement on human chromosome 1q32. This cluster spans a region of 415 kbp and 560 
includes the CFH and five CFH-related CFHR genes. For the CFH and the CFHR4 genes two 561 
transcripts have been identified, which are derived by alternative splicing and which encode 562 
related but distinct proteins (CFH and CFHL1, and CFHR4A and CFHR4B, respectively). 563 
This cluster includes homologous repeat regions (marked as A1-C2) which due to non-allelic 564 
homologous recombination events can result in deletion of large chromosomal fragments. 565 
Depending on the site of recombination as indicated by either the solid or the dotted lines, a 566 
large genomic deletion is observed in this cluster which either results in a CFH:CFHR1 567 
hybrid gene (solid line) or the deletion of CFHR3 and CFHR1 (dotted line). These deletions 568 
predispose to atypical hemolytic uremic syndrome. 569 
(B) The CFH family proteins are plasma glycoproteins, which are exclusively composed of 570 
short consensus repeat (SCR) domains, which are common among complement regulatory 571 
proteins. The individual SCR domains of the CFHR proteins share high sequence identity 572 
with each other and with SCRs of the complement regulator CFH. Homologous domains 573 
identified by sequence similarity are indicated by vertical alignment, and the numbers above 574 
each SCR indicate the identity to the corresponding domain in CFH at the protein level. All 575 
CFHRs contain domains related to the C-terminal surface and ligand recognition region 576 
(SCRs 19-20) and to the middle region (SCRs 6-9) of CFH. CFHR proteins lack SCRs 577 
homologous to the complement regulatory domains (SCRs 1-4) of CFH. The conservation of 578 
the N- and C-termini among the CFHR proteins is indicative of related or even overlapping 579 
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functions. For CFH, the localization of binding domains for C3b and its fragments,as well as 580 
for heparin, and C-reactive protein (CRP) are indicated.   581 
 582 
Figure 2: The related C-terminal regions of CFHRs with the C-terminal CFH surface 583 
binding region indicate binding to common or related surface structures.  584 
The C-termini representing the 2-3 C-terminal SCRs of the five human CFHR proteins are 585 
highly related to the C-terminal surface binding region of CFH. This homology suggests 586 
surface binding activity for each CFHR protein. Three major scenarios can be postulated, 587 
which may occur both in host tissues and on microbial surfaces, as microbes express distinct 588 
surface proteins that can simultaneously bind CFH, CFHL1, CFHR1 or CFHR3, such as 589 
streptococcal M proteins or the CRASP proteins of Borrelia spp. 590 
(A) Independent surface binding with functional synergism. The CFHR3 and CFHR4 proteins 591 
have been shown to enhance complement inhibitory activity of CFH, but alone lack 592 
regulatory activity.  593 
(B) Competition for surface binding via the same ligand was shown for CFHR1 and surface 594 
bound CFH. In this scenario CFHR1 reduced the regulatory activity of CFH at the surface. 595 
Thus, CFHR1 (and possibly other CFHR proteins) can modulate the local activity of CFH. 596 
This may explain why the absence of CFHR1 and CFHR3 is protective against the 597 
development of the ocular disease age related macular degeneration (AMD). 598 
(C) Independent surface binding and independent function. Upon surface binding, the distinct 599 
CFH family proteins may display independent but similar activities (such as the weak 600 
complement regulatory activity of CFHR5, which might be important in the kidney), or exert 601 
different functions. As CFHR proteins also have significant differences in sequence and 602 
domain structure, they may possess so far undiscovered biological activities, which are 603 
unrelated to the complement system. 604 
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Table 1.  Characteristics of human CFH family proteins 
 
Protein Size Appearance in 
plasma 
Known host 
ligands 
Binding to 
Pathogens 
Function References 
CFH 150 kDa glycoprotein, 
associated with HDL 
and LDL 
C3b, C3c, C3d, 
heparin, CRP, and 
others  
 
M protein, 
BbCRASPs 1-5 and 
multiple microbial 
ligands 
cofactor and decay 
accelerating activity, 
cellular adhesion 
3-6, 14, 16-18, 50-
53, 57-64, 66 
CFHL1 42 kDa glycoprotein C3b, heparin, CRP M protein, 
BbCRASPs 1-2 and 
multiple microbial 
ligands 
cofactor and decay 
accelerating activity, 
cellular adhesion 
4, 9, 14, 18, 50, 
51, 53, 58, 59, 62 
CFHR1 37 kDa 
43 kDa 
glycosylated 
isoforms, 
associated with HDL 
 
 
BbCRASPs 3-5, 
multiple microbial 
ligands 
 4, 15, 18, 19, 53, 
57-60, 62, 65, 66 
CFHR2 24 kDa 
29 kDa 
non-glycosylated and 
glycosylated 
isoforms, 
associated with HDL 
   4, 18, 65, 66 
CFHR3 36-50 kDa multiple bands 
(likely differently 
glycosylated forms) 
C3b, C3d, heparin M protein enhances CFH 
cofactor activity 
4, 12, 14, 17, 18 
CFHR4 42 kDa (CFHR4B) 
86 kDa (CFHR4A) 
 
likely splice variants, 
associated with 
chylomicron, LDL 
and VLDL  
C3b, C3d  enhances CFH 
cofactor activity 
4, 12, 17, 18, 66-
68 
CFHR5 65 kDa associated with HDL C3b, heparin, CRP  weak cofactor and 
decay accelerating 
activities 
4, 13, 18, 20 
 
HDL: high density lipoproteins, LDL: low density lipoproteins, VLDL: very low density lipoproteins, BbCRASP: complement regulator 
acquiring surface protein of Borrelia burgdorferi, CRP: C-reactive protein 
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Table 2. Disease-associated mutations and polymorphisms in CFH family genes  
 
 aHUS 
Atypical Hemolytic Uremic 
Syndrome 
MPGN II 
Membranoproliferative 
Glomerulonephritis type II 
AMD 
Age-related Macular 
Degeneration 
references 
CFH heterozygous mutations 
(>75% in SCRs 18-20), 
CFH:CFHR1 hybrid gene, 
gene conversion 
homozygous or compound 
heterozygous mutations 
 
- mutations in Cys residues 
result in a block of  protein 
secretion, 
- deletion of K224 in SCR4, 
- Y402H polymorphism 
V62I, Y402H, T493R 
polymorphisms,  
intronic polymorphisms 
23, 32, 33, 40, 44, 45 
CFHR1 deletion of CFHR1,  
CFH:CFHR1 hybrid gene, 
gene conversion 
 deletion of CFHR1 is 
protective 
27, 29, 30, 44, 45, 46 
CFHR3 deletion of CFHR3  deletion of CFHR3 is 
protective 
27, 44, 45, 46 
CFHR5 L66F* (SCR1), K126N* and 
InsA573/197Stop (SCR3), 
R338H* (SCR6), M496R* 
(SCR9) 
-249T/C and -20T/C promoter 
polymorphisms, 
P46S exchange in SCR1 
 31, 36 
 
* The numbering of amino acids in ref. 31 starts after the 18 amino acid-length signal peptide. 
